NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
NAARDEN, the Netherlands and MIAMI, May 31, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam Pharma" or the "Company"), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET.
亚洲网荷兰纳尔登和迈阿密5月31日电(环球通讯社)-专注于研究和开发治疗主要心脏代谢疾病的变革性口服疗法的临床阶段公司新阿姆斯特丹制药公司(纳斯达克代码:NAMS或“新阿姆斯特丹制药”或“公司”)今天宣布,新阿姆斯特丹制药公司首席执行官迈克尔·戴维森医学博士将出席2023年6月7日(星期三)下午3:30举行的杰富瑞医疗会议。Et.
A live webcast of the presentation will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company's website.
演示文稿的网络直播将通过新阿姆斯特丹制药公司网站的投资者关系部分进行,网址为:Ir.newamsterdampharma.com。在网络直播之后,将在公司网站上进行存档重播。
About NewAmsterdam
关于新阿姆斯特丹
NewAmsterdam Pharma (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally-tolerated statin therapy for high-risk cardiovascular disease ("CVD") patients. Results from NewAmsterdam Pharma's ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). In addition, topline results from NewAmsterdam Pharma's ROSE2 trial evaluating the combination of 10 mg obicetrapib and 10 mg ezetimibe demonstrated a median reduction in LDL-C levels of 59% versus baseline in patients on high-intensity statin therapy (vs. a 6% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam recently completed a business combination with FLAC, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners. Proceeds from this transaction were approximately $328 million, prior to deducting transaction expenses. In June 2022, NewAmsterdam Pharma entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer's disease. For more information, please visit: .
新阿姆斯特丹制药公司(纳斯达克代码:NAMS)是一家临床阶段的生物制药公司,其使命是改善患有心脏代谢性疾病的患者的护理,这些人群目前批准的治疗方法尚未足够成功或耐受性不佳。新阿姆斯特丹正在研究口服、低剂量、每天一次的CETP抑制剂obicetRapib,将其作为高危心血管疾病(CVD)患者最大耐受性他汀类药物的首选降低低密度脂蛋白胆固醇疗法的辅助疗法。新阿姆斯特丹制药公司的ROSE 2b期试验(在2021年的AHA科学会议上公布)的结果包括观察到,在接受高强度他汀类药物治疗的患者中,接受obicetraib 10 mg的患者的低密度脂蛋白-C的中位数下降了51%(而服用安慰剂的患者下降了7%)。此外,来自新阿姆斯特丹制药公司ROSE 2试验的TOPLINE结果表明,在接受高强度他汀类药物治疗的患者中,低密度脂蛋白-C水平比基线降低了59%(而服用安慰剂的患者降低了6%),该试验评估了10毫克奥比曲布和10毫克依折麦布的组合。总部设在荷兰的新阿姆斯特丹最近完成了与FLAC的业务合并,FLAC是一家由Frazier Healthcare Partners的一家附属公司赞助的特殊目的收购公司。在扣除交易费用之前,这笔交易的收益约为3.28亿美元。2022年6月,新阿姆斯特丹制药公司与梅纳里尼集团签订了一项独家许可协议,将obicetRapib在欧洲商业化,同时保留在世界其他地区商业化obicetRapib的所有权利(如果获得批准),以及开发某些形式的obicetRapib治疗阿尔茨海默病等其他疾病的权利。如需更多信息,请访问:。
Company Contact
公司联系人
Matthew Philippe
P: 917-882-7512
matthew.philippe@newamsterdampharma.com
马修·菲利普
电话:917-882-7512
邮箱:matthew.philippe@newamsterDampharma.com
Media Contact
媒体联系人
Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 917-714-2609
bblatstein@spectrumscience.com
代表新阿姆斯特丹的光谱科学
布莱恩·布拉斯坦
电话:917-714-2609
邮箱:bblatstein@spectrumcerence.com
Investor Contact
投资者联系方式
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1 212-362-1200
hannah.deresiewicz@sternir.com
代表新阿姆斯特丹的斯特恩投资者关系
汉娜·德雷谢维奇
电话:1212-362-1200
邮箱:hannah.deresiewicz@sternir.com